Analyst Conference Summaries

Biotechnology Investor Aids

Alexion Pharmaceuticals
ALXN

conference date: April 25, 2019 @ 5:00 AM Pacific Time

Alexion: Priced Right For Long-Term Investors [August 16, 2018 at Seeking Alpha]

I buy Alexion [February 3, 2015 at Dissecting the Bull]

Alexion's Rare Disease Model Analyzed [December 18, 2014 @ Seeking Alpha]

2019
Alexion
Q4 2018
Alexion
Q1 2019
   
Feb. 4, 2019
April 25, 2019    
2018
Feb. 8, 2018
April 12, 2018
July 26, 2018
Oct. 24, 2018
2017
02/16/2017
 04/27/2017
July 27, 2017
Oct. 26, 2017
2016
02/03/2016
04/28/2016
07/28/2016
10/27/2016
2015
01/29/2015
05/23/2015
07/30/2015
10/29/2015
2014
01/30/2014
04/24/2014
07/24/2014
10/23/2014
2013
 
 
 
 
 07/25/2013
10/24/2013 

Alexion Pharmaceuticals (ALXN) is a biotechnology company specializing in rare blood disorders.

Alexion web site
Alexion investor relations page

I owned Alexion between February 3, 2015 and May 18, 2017, took my losses, illustrating the danger in investing in a priced-over-perfection stock. Price was pretty reasonable when I sold it, but I had just had a major gain with GlycoMimetics, and decided to reduce my debt.

I reserve the right to buy or sell the stock at any time without notice. Investors are welcome to read my notes and opinions, which are journalism, not financial advice.

 

Search

More Analyst Conference Pages:

 AGEN
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CELG
 EPZM
 GILD
 GLYC
 INCY
 INO
 ISRG
 MCHP
 MYL
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2015 William P. Meyers